COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Clinical trial NCT04068610 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT04068610

Sponsor

MedImmune LLC

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2019-09-13

Primary completion

2022-10-10

Enrollment

61

View on ClinicalTrials.gov